相似文献
1
OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics.OPT：一套用于临床药代动力学参数优化的计算机程序。
Br J Clin Pharmacol. 1982 Aug;14(2):247-56. doi: 10.1111/j.1365-2125.1982.tb01969.x.
2
A package of computer programs designed to simulate pharmacokinetic monitoring of drug therapy.
Comput Programs Biomed. 1980 Dec;12(2-3):85-95. doi: 10.1016/0010-468x(80)90054-9.
3
Parameter optimisation in clinical pharmacokinetics.临床药代动力学中的参数优化
Comput Programs Biomed. 1982 Jun;14(3):239-48. doi: 10.1016/0010-468x(82)90029-0.
4
Pharmacokinetics in patients with cardiac failure.心力衰竭患者的药代动力学。
Clin Pharmacokinet. 1976 Nov-Dec;1(6):389-405. doi: 10.2165/00003088-197601060-00001.
5
The use of computers in pharmacokinetics.计算机在药代动力学中的应用。
Int J Clin Pharmacol Biopharm. 1978 Aug;16(8):345-50.
6
The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.丙吡胺和单-N-脱烷基丙吡胺在人体内的药代动力学。
Int J Clin Pharmacol Ther Toxicol. 1982 May;20(5):219-26.
7
Computerized drug therapy: application of the hand-held microcomputer to dosage regimen design.
Int J Biomed Comput. 1985 Jul;17(1):49-55. doi: 10.1016/0020-7101(85)90072-8.
8
Steady-state dosage regimen calculations in linear pharmacokinetics.
Int J Biomed Comput. 1986 May;18(3-4):167-82. doi: 10.1016/0020-7101(86)90014-0.
9
Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.丙吡胺在犬体内的药代动力学及稳态心肌摄取情况
Drug Metab Dispos. 1978 May-Jun;6(3):338-45.
10
A nonlinear physiologic pharmacokinetic model: I. Steady-state.一种非线性生理药代动力学模型：I. 稳态
J Pharmacokinet Biopharm. 1985 Feb;13(1):73-92. doi: 10.1007/BF01073657.
引用本文的文献
1
Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I.胸段移植中免疫抑制治疗的药代动力学优化：第一部分。
Clin Pharmacokinet. 2009;48(7):419-62. doi: 10.2165/11317230-000000000-00000.
2
Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery.心脏胸外科手术后肾功能不稳定患者庆大霉素和万古霉素的群体药代动力学建模
Br J Clin Pharmacol. 2006 Feb;61(2):164-76. doi: 10.1111/j.1365-2125.2005.02547.x.
3
Flucytosine dose requirements in a patient receiving continuous veno-venous haemofiltration.接受持续静脉-静脉血液滤过治疗的患者的氟胞嘧啶剂量需求
Intensive Care Med. 2002 Jul;28(7):999. doi: 10.1007/s00134-002-1340-4.
4
Bayesian forecasting in paediatric populations.儿科人群中的贝叶斯预测
Clin Pharmacokinet. 1996 Nov;31(5):325-30. doi: 10.2165/00003088-199631050-00001.
5
Bayesian individualization via sampling-based methods.
J Pharmacokinet Biopharm. 1996 Feb;24(1):103-31. doi: 10.1007/BF02353512.
6
Value of theophylline treatment in patients handicapped by chronic obstructive lung disease.茶碱治疗对慢性阻塞性肺疾病患者的价值。
Thorax. 1993 Mar;48(3):227-32. doi: 10.1136/thx.48.3.227.
7
Prediction of response to theophylline in chronic bronchitis.慢性支气管炎患者对茶碱反应的预测
Br J Clin Pharmacol. 1984 Jan;17(1):1-8. doi: 10.1111/j.1365-2125.1984.tb04990.x.
8
Estimation of gentamicin clearance and volume of distribution in neonates and young children.新生儿和幼儿庆大霉素清除率及分布容积的估算。
Br J Clin Pharmacol. 1984 Nov;18(5):685-92. doi: 10.1111/j.1365-2125.1984.tb02530.x.
9
Clinical pharmacokinetics: a comprehensive system for therapeutic drug monitoring and prescribing.临床药代动力学：治疗药物监测与处方的综合系统。
Br Med J (Clin Res Ed). 1984 Feb 18;288(6416):541-5. doi: 10.1136/bmj.288.6416.541.
10
Performance of Bayesian feedback to forecast lidocaine serum concentration: evaluation of the prediction error and the prediction interval.贝叶斯反馈预测利多卡因血清浓度的性能：预测误差和预测区间的评估。
J Pharmacokinet Biopharm. 1985 Apr;13(2):203-12. doi: 10.1007/BF01059399.
本文引用的文献
1
Disposition kinetics of disopyramide in patients with renal insufficiency.肾功能不全患者中丙吡胺的处置动力学
Biopharm Drug Dispos. 1980 Jan-Mar;1(3):133-40. doi: 10.1002/bdd.2510010308.
2
Predicting individual phenytoin dosage.
J Pharmacokinet Biopharm. 1981 Apr;9(2):131-46. doi: 10.1007/BF01068078.
3
The prediction of individual systolic time interval v heart rate regression equations.个体收缩期时间间隔与心率回归方程的预测。
Br J Clin Pharmacol. 1981 Jul;12(1):21-30. doi: 10.1111/j.1365-2125.1981.tb01850.x.
4
Disopyramide pharmacokinetics during recovery from myocardial infarction.心肌梗死恢复期的丙吡胺药代动力学。
Br J Clin Pharmacol. 1982 Mar;13(3):417-21. doi: 10.1111/j.1365-2125.1982.tb01395.x.
5
Serum digoxin in adults and children.
Int J Clin Pharmacol. 1973 Apr;7(2):219-22.
6
Improved computer-assisted digoxin therapy. A method using feedback of measured serum digoxin concentrations.
Ann Intern Med. 1975 May;82(5):619-27. doi: 10.7326/0003-4819-82-5-619.
7
Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.根据常规临床数据估算药代动力学参数的群体特征。
J Pharmacokinet Biopharm. 1977 Oct;5(5):445-79. doi: 10.1007/BF01061728.
8
Disopyramide serum and pharmacologic effect kinetics applied to the assessment of bioavailability.丙吡胺血清及药理效应动力学在生物利用度评估中的应用。
Br J Clin Pharmacol. 1978 Nov;6(5):409-19. doi: 10.1111/j.1365-2125.1978.tb04605.x.
9
Forecasting individual pharmacokinetics.预测个体药代动力学。
Clin Pharmacol Ther. 1979 Sep;26(3):294-305. doi: 10.1002/cpt1979263294.
10
Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol.影响茶碱清除率的因素：年龄、烟草、大麻、肝硬化、充血性心力衰竭、肥胖、口服避孕药、苯二氮䓬类药物、巴比妥类药物和乙醇。
J Pharm Sci. 1979 Nov;68(11):1358-66. doi: 10.1002/jps.2600681106.
Zotero 插件